Ascend Advanced Therapies vs Genezen: CDMO Comparison

How does Ascend Advanced Therapies compare to Genezen for AAV manufacturing?

Side-by-side comparison of Ascend Advanced Therapies and Genezen on independent FDA inspections, EMA and MHRA GMP certificates, clinical-program activity, and CDMO Signal Score. Data sourced from FDA, EMA EudraGMDP, MHRA GMDP, and ClinicalTrials.gov.

Rockville, MD · Alachua, FL · Munich, DE
Signal Score
78/100
Quality (FDA + GMP)
100/100
FDA inspections
0
FDA warning letters
0
EMA GMP certificates (active)
1
MHRA GMP certificates (compliant)
0
Clinical programs (matched)
0
Capacity
—
Modalities
AAV, Lentiviral, Plasmid
Indianapolis, IN · Lexington, MA
Signal Score
78/100
Quality (FDA + GMP)
100/100
FDA inspections
1
— NAI / VAI / OAI
1 / 0 / 0
FDA warning letters
0
EMA GMP certificates (active)
0
MHRA GMP certificates (compliant)
0
Clinical programs (matched)
0
Capacity
Available
Modalities
AAV, Lentiviral

Key differences

  • Genezen has FDA inspections on record (1); Ascend Advanced Therapies does not yet appear in the FDA inspection database.
  • Both maintain clean enforcement records — no FDA OAI classifications or warning letters on file for either CDMO.
  • Ascend Advanced Therapies holds 1 active EMA GMP certificates; Genezen does not appear in EudraGMDP.

On a 13-modality CDMO landscape, both Ascend Advanced Therapies and Genezen qualify as AAV manufacturers; Ascend Advanced Therapies carries the higher composite Signal Score for AAV programs in this comparison.

What to evaluate for AAV programs

Both Ascend Advanced Therapies and Genezen qualify as AAV CDMOs. When choosing between them for AAV programs, weigh these four dimensions specifically — each carries through to the side-by-side scorecard above.

Platform & scale

Suspension processes scale better than adherent (HEK293) for commercial volumes. Confirm the CDMO's largest validated bioreactor scale and serotype track record.

Capsid quality

Full/empty capsid ratio and aggregate control drive potency and safety. Ask about AUC, anion-exchange separation, and the analytics package for capsid characterization.

Regulatory readiness

For programs heading to BLA, a strong FDA inspection history and EMA/MHRA GMP coverage matter — both are shown above and on each profile.

Capacity & timelines

AAV manufacturing slots can be constrained. Weigh the capacity signal and clinical-program load before committing.

See all AAV CDMOs ranked by Signal Score →

Frequently asked: Ascend Advanced Therapies vs Genezen

How does Ascend Advanced Therapies compare to Genezen for AAV manufacturing?

On CDMO Signal's composite Signal Score, Ascend Advanced Therapies is 78/100 and Genezen is 78/100; Ascend Advanced Therapies has 0 FDA inspections on record vs 1 for Genezen; European coverage is 1 active EMA+MHRA certificate for Ascend Advanced Therapies vs 0 for Genezen. Both are tracked in the CDMO Signal directory as AAV CDMOs. The scorecard above breaks down every metric side by side — use it alongside each CDMO's individual profile for the full regulatory and clinical footprint.

Which has the stronger FDA inspection record, Ascend Advanced Therapies or Genezen?

Both Ascend Advanced Therapies and Genezen maintain clean enforcement records on file — no FDA warning letters and no OAI classifications. Ascend Advanced Therapies has 0 FDA inspections on record; Genezen has 1.

How do Ascend Advanced Therapies and Genezen compare on European GMP coverage?

Ascend Advanced Therapies holds 1 active EMA GMP certificate and 0 MHRA / UK certificates. Genezen holds 0 active EMA GMP certificates and 0 MHRA / UK certificates. Use these counts as a proxy for the breadth of each CDMO's European regulatory footprint.

Which is better for AAV manufacturing — Ascend Advanced Therapies or Genezen?

Both Ascend Advanced Therapies and Genezen are tagged as AAV CDMOs in our directory, so both are credible options for AAV programs. The most important differentiator for AAV selection is typically platform & scale: Suspension processes scale better than adherent (HEK293) for commercial volumes. Confirm the CDMO's largest validated bioreactor scale and serotype track record. Review each CDMO's profile and inspection record before shortlisting.

What does the Signal Score gap mean in practice?

Ascend Advanced Therapies carries a Signal Score of 78/100 and Genezen carries 78/100 — essentially tied for Genezen. The Signal Score combines quality (FDA inspections + EMA/MHRA GMP), operational performance, financial stability, and capacity intelligence. CDMOs cannot pay to influence their score.

Evaluating Ascend Advanced Therapies and Genezen for a program?

Use the free AI matchmaker to weigh both against your specific requirements — capacity, modality, regulatory record, geography — and surface other qualified options.

Find & compare CDMOs →
Sourced from FDA, EMA EudraGMDP, MHRA GMDP, and ClinicalTrials.gov.